Monday, 31 August 2026European Markets

TERACT Stock Bullish By 21% In The Last 5 Sessions

Loading stream...

(VIANEWS) - Shares of TERACT (CAC 40: TRACT.PA) rose by a staggering 21.67% in 5 sessions from $6.09 to $7.41 at 16:16 EST on Tuesday, after four successive sessions in a row of gains. CAC 40 is sliding 0.07% to $7,132.35, following the last session's downward trend.

About TERACT

Teract S.A. operates in retail business in Europe. The company operates through Garden Centre Retailer and Marketer segments. It operates garden centers and pet care shops under the Jardiland, Gamm vert, Delbard, and Jardinerie du Terroir brand names. The company also operates in the fresh, local, and organic produce sector under Frais d'Ici and Bio&Co brands with food outlets. It operates 1,597 stores. The company is based in Paris, France.

Volatility

TERACT's last week, last month's, and last quarter's current intraday variation average was 4.91%, 0.90%, and 1.33%.

TERACT's highest amplitude of average volatility was 4.91% (last week), 1.69% (last month), and 1.33% (last quarter).

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions,

TERACT's stock is considered to be oversold (<=20).

More news about TERACT (TRACT.PA).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Hawkish Fed Signals at Jackson Hole Pressure Rate-Sensitive Assets
Kevin Warsh's hawkish inflation remarks at Jackson Hole, alongside a steady drumbeat of Federal Reserve testimony from Powell, Barr, Bowman and other officials on supervision, regulation and monetary policy, signal continued vigilance against inflation rather than an imminent easing cycle. Rate-sensitive and precious-metals-linked names such as SSR Mining sold off the same day, consistent with markets repricing for a firmer-for-longer policy stance.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
Checked against the original source
4,979
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,979 facts checked against source5,261 source documents archived
Query this data → isubstrate.com